Management of age-related macular degeneration
Pro Research Analysisby 
Searched over 200M research papers
Overview of Age-Related Macular Degeneration (AMD) Management
Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss in older adults, with both dry (atrophic) and wet (neovascular/exudative) forms. Management strategies differ based on the stage and type of AMD, focusing on slowing disease progression and preserving vision rather than restoring lost sight 1237.
Diagnosis and Monitoring in AMD
Modern diagnosis of AMD has shifted from basic ophthalmoscopy to a multimodal imaging approach, which improves accuracy in detecting and monitoring disease progression. Functional assessments now include alternatives to standard visual acuity tests, and self-monitoring is encouraged for early detection of changes .
Management of Early and Intermediate AMD: Nutritional and Lifestyle Interventions
For early and intermediate AMD, there is no cure, but progression can be slowed. Dietary supplements, particularly those used in the Age-Related Eye Disease Study (AREDS), including antioxidants and zinc, are recommended to reduce the risk of progression to advanced AMD 1257. Carotenoids such as lutein, zeaxanthin, and meso-zeaxanthin have shown neuroprotective effects and may improve visual function, serving as adjunctive nutraceutical therapies . Lifestyle modifications, including a healthy diet, are also emphasized .
Management of Advanced Dry AMD (Geographic Atrophy)
Currently, there is no effective treatment for geographic atrophy, the advanced form of dry AMD. However, recent clinical trials have shown that intravitreal anti-complement agents like pegcetacoplan and avacincaptad pegol can slow the growth of geographic atrophy, offering hope for future management options. Other investigational therapies include complement pathway inhibitors, visual cycle modulators, antioxidative therapy, neuroprotective agents, gene therapy, and stem cell therapy 24710.
Management of Wet (Neovascular) AMD: Anti-VEGF and Other Therapies
The introduction of anti-vascular endothelial growth factor (anti-VEGF) therapy has revolutionized the treatment of wet AMD, significantly improving visual outcomes and becoming the standard of care 2356+2 MORE. However, not all patients respond adequately, and repeated injections can be burdensome. Newer agents, such as designed ankyrin repeat proteins (DARPins), may offer longer-lasting effects and reduce treatment frequency . Other established treatments include laser photocoagulation and photodynamic therapy, though these are less commonly used today 16.
Emerging and Future Therapies for AMD
Research is ongoing into molecular targeting, stem cell therapy, nanotechnology, exosomes, and advanced drug delivery systems. Artificial intelligence and 3D printing are also being explored for their potential to improve diagnosis and treatment . Visual rehabilitation, including low-vision aids and rehabilitation programs, remains important for patients with significant vision loss while awaiting more restorative therapies such as optogenetics, stem cells, or artificial retina technologies 24.
Controversies and Disparities in AMD Management
Despite advances, controversies remain regarding the cost, accessibility, and long-term burden of current treatments, as well as disparities in care and the need for further research to address these issues .
Conclusion
The management of age-related macular degeneration is multifaceted, involving nutritional interventions, anti-VEGF therapies, emerging pharmacological and surgical options, and visual rehabilitation. While significant progress has been made, especially for wet AMD, ongoing research is crucial to address the unmet needs in dry AMD and to develop more effective, accessible, and less burdensome treatments for all patients 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic
Management of age-related macular degeneration.
Laser photocoagulation and photodynamic therapy are effective treatments for age-related macular degeneration, preserving residual vision and potentially preventing disease progression in early cases.
Recent theranostic paradigms for the management of Age-related macular degeneration.
Recent advances in molecular targeting, stem cell therapy, nanotechnology, and exosomes, along with artificial intelligence and 3D printing, show promise in managing Age-related macular degeneration.
DOI